DCVC Bio, L.P. 3
3 · AbCellera Biologics Inc. · Filed Dec 11, 2020
Insider Transaction Report
Form 3
DCVC Bio, L.P.
10% Owner
Holdings
- (indirect: See footnote)
Convertible Note
Exercise: $17.00→ Common Shares (29,411 underlying) - (indirect: See footnote)
Series A1 Preferred Shares
→ Common Shares (21,052,640 underlying) - (indirect: See footnote)
Series A2 Preferred Shares
→ Common Shares (8,023,710 underlying)
Footnotes (4)
- [F1]The Series A1 Preferred Shares and Series A2 Preferred Shares (collectively, the "Preferred Shares") are convertible into Common Shares at a 1:10 ratio into the number of Common Shares as shown in Column 3 at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Preferred Shares have no expiration date.
- [F2]These securities are held by DCVC Bio, L.P. ("DCVC Bio"). DCVC Bio GP, LLC ("DCVC Bio GP") is the general partner of DCVC Bio and has sole voting and dispositive power with regard to the securities held by DCVC Bio. JNK Capital Management, LLC ("JNK") and ZNM Capital Management, LLC ("ZNM") are the managing members of DCVC Bio GP and share voting and dispositive power with respect to the securities held by DCVC Bio. The managing members of JNK and ZNM are Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead. Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead share voting and dispositive power with respect to the securities held by DCVC Bio.
- [F3](Continued from Footnote 2) Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that it is the beneficial owner of such securities, except to the extent of its indirect pecuniary interest therein, if any.
- [F4]The convertible promissory note ("Convertible Note") has a maturity date of October 30, 2025 and the principal amount of the Convertible Note will convert upon the closing of the IPO into Common Shares at a conversion price equal to $17.00 per Common Share.